MoonLake Immunotherapeutics (MLTX)
| Market Cap | 823.02M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -64.51M |
| Shares Out | 39.15M |
| EPS (ttm) | -1.70 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 210,234 |
| Open | 22.13 |
| Previous Close | 22.13 |
| Day's Range | 20.14 - 22.18 |
| 52-Week Range | 4.25 - 25.32 |
| Beta | 0.93 |
| Analysts | Buy |
| Price Target | 22.27 (+5.95%) |
| Earnings Date | Mar 20, 2023 |
About MLTX
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or radiographic axial spondyloarthritis. MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland. [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 13 analysts, the average rating for MLTX stock is "Buy." The 12-month stock price forecast is $22.27, which is an increase of 5.95% from the latest price.
News
MoonLake Immunotherapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Provides a Business Update
MoonLake Immunotherapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Provides a Business Update
MoonLake Immunotherapeutics completes patient enrollment and randomization ahead of schedule in a Phase 2 trial of the Nanobody® sonelokimab in moderate-to-severe hidradenitis suppurativa
MoonLake Immunotherapeutics com pletes patient enrol l ment and randomization ahead of schedule in a Phase 2 trial of the Nanobody ® sonelokimab in moderate-to-severe hidradenitis suppurativa
MoonLake Immunotherapeutics screens first patient in Phase 2 study of the Nanobody® sonelokimab in active psoriatic arthritis
MoonLake Immunotherapeutics screens first patient in Phase 2 study of the Nanobody ® sonelokimab in active psoriatic arthritis
MoonLake Immunotherapeutics Reports Third Quarter 2022 Financial Results and Provides Recent Business Update
MoonLake Immunotherapeu tics Reports Third Quarter 2022 Financial Results and Provides Recent Business Update
MoonLake Immunotherapeutics to initiate global Phase 2 study of the Nanobody® sonelokimab in patients with active psoriatic arthritis
MoonLake Immunotherapeutics to i nitiate g lobal Phase 2 s tudy of the Nanobody ® s onelokimab in p atients with active psoriatic arthritis
MoonLake Immunotherapeutics signs development and manufacturing agreement with Vetter Pharma International GmbH
MoonLake Immunotherapeutics signs development and manufacturing agreement with Vetter Pharma International GmbH
HC Wainwright Starts Coverage On This 'Best-In-Class Agent For Inflammatory Disorders
HC Wainwright initiated coverage on MoonLake Immunotherapeutics (NASDAQ: MLTX) with a Buy rating and a price target of $28, citing a potentially best-in-class agent for multiple inflammatory disorders...
Why MoonLake Immunotherapeutics Shares Are Surging Higher Today
MoonLake Immunotherapeutics (NASDAQ: MLTX) shares are trading approximately 23% higher Tuesday morning on high volume. MoonLake's average session volume over a 100-day period is about 158,900, accordi...
MoonLake Immunotherapeutics starts Phase 2 trial of the Nanobody® Sonelokimab in patients with moderate-to-severe hidradenitis suppurativa
MoonLake Immunotherapeutics starts Phase 2 trial of the Nanobody® Sonelokimab in patients with moderate-to-severe hidradenitis suppurativa
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into the Fairness of the Merger of Helix Acquisition Corp. with MoonLake Immunotherapeutics AG
New York, New York--(Newsfile Corp. - October 4, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All Persons or Entities who purchased Helix Acquisition Corp. (NASDAQ: HL...
MoonLake Immunotherapeutics AG and Helix Acquisition Corp. Announce Business Combination Agreement to Create Publicly Listed Biotechnology Company Advancing Tri-specific Nanobody® Sonelokimab
ZUG, Switzerland & BOSTON--(BUSINESS WIRE)--MoonLake Immunotherapeutics AG, a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory skin and joint diseases and...
Helix Acquisition Corp. Announces Closing of $115 Million Initial Public Offering, Including the Full Exercise of the Underwriter's Option to Purchase Additional Shares
Boston, Massachusetts--(Newsfile Corp. - October 22, 2020) - Helix Acquisition Corp. (NASDAQ: HLXA) (the "Company") announced today that on Oct. 22, 2020 it closed its initial public offering of 11,50...
Helix Acquisition Corp. Announces Pricing of $100 Million Initial Public Offering
Boston, Massachusetts--(Newsfile Corp. - October 19, 2020) - Helix Acquisition Corp. (the "Company") announced today that it priced its initial public offering of 10,000,000 Class A ordinary shares at...